metenkefalin
Small moleculeexperimental
Met-enkephalin, also known as metenkefalin (INN), sometimes referred to as opioid growth factor (OGF), is a naturally occurring, endogenous opioid peptide that has opioid effects of a relatively short duration. It is one of the two forms of enkephalin, the other being leu-enkephalin. The enkephalins are considered to be the primary endogenous ligands of the δ-opioid receptor, due to their high potency and selectivity for the site over the other endogenous opioids. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2003 (NCT00109941)
Timeline
Indications
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108291 ↗
- WikipediaMet-enkephalin ↗
Also known as
- met5-enkephalin
- met5-enkephalin
- metenkefalin
- metenkephalin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04374032 | Phase 2/Phase 3 (Phase 3) | May 1, 2020 | Kocaeli University |
| NCT03283397 | Phase 3 | Nov 4, 2018 | Kocaeli University, MonitorCRO |
| NCT00706576 | Phase 1 | Jun 1, 2008 | Pennsylvania State University |
| NCT00109941 | Phase 2 | Oct 1, 2003 | Pennsylvania State University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kocaeli University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Pennsylvania State University | Academic/Hospital | 2 | 2 | 2 | 2003 |
| MonitorCRO | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1